(32 days)
Not Found
Not Found
No
The summary describes a physical probe and seal for measuring blood oxygen saturation, with no mention of software, algorithms, or data processing that would suggest AI/ML. The modifications are material changes (Heparin coating, tubing material).
No
The device is described as being used for continuous in vivo measurement of oxyhemoglobin saturation, pressure monitoring, and infusion of fluids, which are diagnostic and supportive functions rather than direct therapeutic interventions.
Yes
Explanation: The device is intended for "measuring the oxygen saturation of blood" and is "indicated for the continuous in vivo measurement of the oxyhemoglobin saturation of blood in the central venous system (ScvO2) for monitoring hemodynamic status during metabolic, respiratory, cardiovascular, and/or other physiological system(s) compromise". These functions clearly fall under diagnostic purposes as they involve identifying or monitoring conditions related to health.
No
The device description clearly outlines physical components like probes, seals, lumens, and tubing, indicating it is a hardware device, not software-only.
Based on the provided text, the OPTICATH® Central Venous Oximetry Probe with Fluidic Seal (Heparin Coated) is not an In Vitro Diagnostic (IVD).
Here's why:
- Intended Use: The intended use is for "continuous in vivo measurement of the oxyhemoglobin saturation of blood in the central venous system (ScvO2)". "In vivo" means within a living organism. IVDs are designed to perform tests on samples taken from the body (in vitro).
- Device Description: The device is described as a "probe" that is inserted into a central venous catheter for "continuous monitoring". This further supports its use within the body.
- Lack of mention of sample analysis: The description focuses on the probe's function within the central venous system and its ability to measure oxygen saturation directly. There is no mention of collecting blood samples or performing tests on those samples outside of the body.
Therefore, the device is an in vivo diagnostic device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The OPTICATH® Central Venous Oximetry Probe with Fluidic Seal (Heparin Coated) is intended for measuring the oxygen saturation of blood.
The OPTICATH® Central Venous Oximetry Probe with Fluidic Seal (Heparin Coated) is indicated for the continuous in vivo measurement of the oxyhemoglobin saturation of blood in the central venous system (ScvO2) for monitoring hemodynamic status during metabolic, respiratory, cardiovascular, and/or other physiological system(s) compromise in accordance with hospital protocols or current Clinical Standards of Practice. The probe with fluidic seal is also indicated for pressure monitoring, and infusion of fluids.
Product codes
DQE
Device Description
The Central Venous Oximetry Probes (Heparin Coated) are non-pyrogenic, sterile, single patient use, disposable oxygenation monitoring sets for use with central venous catheters for continuous monitoring of central venous oxygen saturation. The probes are manufactured from medical-grade polymers and incorporate a closed-ended fiber optic lumen at the tip to measure central venous oxygen saturation. The exterior of the proposed device is coated with Heparin using the same Heparin agent and coating method used on Oximetry Catheters being marketed by Hospira today. The method of operation is the same as the predicate OPTICATH® Central Venous Oximetry Probe with Fluidic Seal.
The Fluidic Seal is a non-pyrogenic, sterile, single patient use device that facilitates the introduction of a Central Venous Oximetry Probe into any size-compatible central venous catheter. The Fluidic Seal also maintains the relative insertion of the oximetry probe within the central venous catheter. The Fluidic Seal consists of a lateral flush port for the administration of fluids and/or for pressure monitoring.
The subject devices are modifications of the predicate OPTICATH® Central Venous Oximetry Probe with Fluidic Seal.
The modification is to add Heparin coating to the probe and change the lead tubing material to a PE-lined polyvinyl chloride.
Both the predicate and the proposed devices can be used with marketed central venous catheters for obtaining critical cardiac performance parameters.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
central venous system
Indicated Patient Age Range
Not Found
Intended User / Care Setting
hospital protocols or current Clinical Standards of Practice
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Not Found
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
OPTICATH® Central Venous Oximetry Probe with Fluidic Seal
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.1230 Fiberoptic oximeter catheter.
(a)
Identification. A fiberoptic oximeter catheter is a device used to estimate the oxygen saturation of the blood. It consists of two fiberoptic bundles that conduct light at a desired wavelength through blood and detect the reflected and scattered light at the distal end of the catheter.(b)
Classification. Class II (performance standards).
0
K062999 page 1/2
510(k) Summary
Name of Submitter:
HOSPIRA. Incorporated 275 North Field Drive Lake Forest, Illinois 60045 Owner/Operator #: 9063339
Nilly - 3 2005
Manufacturer and Establishment Registration Number:
| Manufacturing Site: | Sterilization Site: |
|---|---|
| ICU MEDICAL (UTAH), INC. | |
| 4455 Atherton Dr. | |
| Salt Lake City, UT 84123 | Isomedix Operations, Inc. |
| 9120 South 150 East | |
| East Sandy, UT 84070 | |
| Establishment Registration #: 1713468 | Establishment Registration #: 1720929 |
Proprietary or Trade Name of Proposed Device: Opticath® Central Venous Oximetry Probe with Fluidic Seal (Heparin Coated)
Common Name: Fiberoptic Oximetry Catheter
Device Classification, Pancode and ProCode: Class II, 78-DQE
Performance Standards: No performance standards have been established under Section 514 of the Food, Drug and Cosmetic Act for Fiberoptic Oximetry Catheters. Fiberoptic oximeter catheters are regulated within 21 CFR 870.1230.
Intended Use / Indications for Use:
The OPTICATH® Central Venous Oximetry Probe with Fluidic Seal (Heparin Coated) is intended for measuring the oxygen saturation of blood.
The OPTICATH® Central Venous Oximetry Probe with Fluidic Seal (Heparin Coated) is indicated for the continuous in vivo measurement of the oxyhemoglobin saturation of blood in the central venous system (ScvO2) for monitoring hemodynamic status during metabolic, respiratory, cardiovascular, and/or other physiological system(s) compromise in accordance with hospital protocols or current Clinical Standards of Practice. The probe with fluidic seal is also indicated for pressure monitoring, and infusion of fluids.
Proposed Device Description:
The Central Venous Oximetry Probes (Heparin Coated) are non-pyrogenic, sterile, single patient use, disposable oxygenation monitoring sets for use with central venous catheters for continuous monitoring of central venous oxygen saturation. The probes are manufactured from medical-grade polymers and incorporate a closed-ended fiber optic lumen at the tip to measure central venous oxygen saturation. The exterior of the proposed device is coated with Heparin using the same Heparin agent and coating method used on Oximetry Catheters being marketed by Hospira today. The method of operation is the same as the predicate OPTICATH® Central Venous Oximetry Probe with Fluidic Seal.
The Fluidic Seal is a non-pyrogenic, sterile, single patient use device that facilitates the introduction of a Central Venous Oximetry Probe into any size-compatible central venous catheter. The Fluidic Seal also maintains the relative insertion of the oximetry probe within the central venous catheter. The Fluidic Seal consists of a lateral flush port for the administration of fluids and/or for pressure monitoring.
1
K062999 page 2/2
The subject devices are modifications of the predicate OPTICATH® Central Venous Oximetry Probe with Fluidic Seal.
The modification is to add Heparin coating to the probe and change the lead tubing material to a PE-lined polyvinyl chloride.
Both the predicate and the proposed devices can be used with marketed central venous catheters for obtaining critical cardiac performance parameters.
Summary of Substantial Equivalence
imary of Substantial Equivalence
The OPTICATH® Central Venous Oximetry Probe with Fluidic Seal (Heparis Crums) Version Cormers The OPTICATH - Central Venous Oximely Prooe Micate OPTICATH® Central Venous Oximetry ans Judineston is Seal with respect to the following characteristics:
Similarities:
-
- Both devices have the same intended use
-
- Doth devices have the banting principles are the same for both devices
-
- The materials used to manufacture the device and the sterilization is the same.
Difference:
- The OPTICATH® Central Venous Oximetry Probe with Fluidic Seal (Heparin Coated) is heparin coated
Statement of Safety and Effectiveness
ethen of Salery and Bircetry Probe with Fluidic Seal (Heparin Coated) meets the The OF I ICA I I Central Venous Oximed in the product labeling, and is as safe and effective in tunctional claims and michded use as deseriods in the producting.
terms of substantial equivalence as the predicate OPTICATH® Central Venous Oximetry Probe with Fluidic Seal.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three curved lines representing its body and wings. The text "DEPARTMENT OF HEALTH AND HUMAN SERVICES USA" is arranged in a circular pattern around the eagle.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
NOV - 3 2006
Hospira, Inc. c/o Ms. Diane Rennpferd Sr. Associate, Global Regulatory Affairs - Devices Dept 389 Bldg H2 275 N Field Drive Lake Forest IL 60045-5046
Re: K062999
Trade/Device Name: OPTICATH Central Venous Oximetry Probe with Seal with Heparin Regulation Number: 21 CFR 870.1230 Regulation Name: Fiberoptic Oximeter Catheter Regulatory Class: Class II (performance standards) Product Code: DQE Dated: September 29, 2006 Received: October 2, 2006
Dear Ms. Rennpferd:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21
3
Page 2 – Ms. Diane Rennpferd
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This Ictter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
B. Zimmer for
Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Number (if known) K062999
| Device Name: | Central Venous Oximetry Probe with Fluidic Seal (Heparin Coated) |
|---|---|
| -------------- | ------------------------------------------------------------------ |
Indications for Use:
The OPTICATH® Central Venous Oximetry Probe with Fluidic Seal (Heparin Coated) is intended for measuring the oxygen saturation of blood.
The OPTICATH® Central Venous Oximetry Probe with Fluidic Seal (Heparin Coated) is indicated for the continuous in vivo measurement of the oxyhemoglobin saturation of blood in the central venous system (ScvO2) for monitoring hemodynamic status during metabolic, respiratory, cardiovascular, and/or other physiological system(s) compromise in accordance with hospital protocols or current Clinical Standards of Practice. The probe with fluidic seal is also indicated for pressure monitoring, and infusion of fluids.
Prescription Use X (Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (Part 21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Bimmlema
7 -1010-1 ascular Devices
Page 1 of 1